Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay by 조상래 & 이은계
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2011, p. 932–940 Vol. 49, No. 3
0095-1137/11/$12.00 doi:10.1128/JCM.02271-10
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Rapid Detection of Fluoroquinolone-Resistant and Heteroresistant
Mycobacterium tuberculosis by Use of Sloppy Molecular Beacons
and Dual Melting-Temperature Codes in a
Real-Time PCR Assay†
Soumitesh Chakravorty,1 Bola Aladegbami,1‡ Kimberley Thoms,1§ Jong Seok Lee,2 Eun Gae Lee,3,4
Vignesh Rajan,4 Eun-Jin Cho,2 Hyunchul Kim,2 Hyunkyung Kwak,2 Natalia Kurepina,5
Sang-Nae Cho,2,3 Barry Kreiswirth,5 Laura E. Via,4
Clifton E. Barry III,4 and David Alland1*
Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenc¸o Center for the Study of Emerging and
Reemerging Pathogens, New Jersey Medical School, Newark, New Jersey1; Department of Microbiology,
International Tuberculosis Research Center, Changwon, Gyeongsang, Republic of Korea2; Department of
Microbiology, School of Medicine, Yonsei University, Republic of Korea3; Tuberculosis Research Section,
LCID, NIAID, NIH, Bethesda, Maryland4; and Public Health Research Institute,
New Jersey Medical School, Newark, New Jersey5
Received 10 November 2010/Accepted 21 December 2010
Fluoroquinolones (FQ) are important second-line drugs to treat tuberculosis; however, FQ resistance is an
emerging problem. Resistance has been mainly attributed to mutations in a 21-bp region of the Mycobacterium
tuberculosis gyrA gene, often called the quinolone resistance-determining region (QRDR). We have developed
a simple, rapid, and specific assay to detect FQ resistance-determining QRDR mutations. The assay amplifies
theM. tuberculosis gyrAQRDR in an asymmetrical PCR followed by probing with two sloppy molecular beacons
(SMBs) spanning the entire QRDR. Mutations are detected by melting temperature (Tm) shifts that occur
when the SMBs bind to mismatched sequences. By testing DNA targets corresponding to all known QRDR
mutations, we found that one or both of the SMBs produced a Tm shift of at least 3.6°C for each mutation,
making mutation detection very robust. The assay was also able to identify mixtures of wild-type and mutant
DNA, with QRDR mutants identified in samples containing as little as 5 to 10% mutant DNA. The assay was
blindly validated for its ability to identify the QRDR mutations on DNA extracted from clinical M. tuberculosis
strains. Fifty QRDR wild-type samples, 34 QRDR mutant samples, and 8 heteroresistant samples containing
mixtures of wild-type and mutant DNA were analyzed. The results showed 100% concordance to conventional
DNA sequencing, including a complete identification of all of the mixtures. This SMB Tm shift assay will be a
valuable molecular tool to rapidly detect FQ resistance and to detect the emergence of FQ heteroresistance in
clinical samples from tuberculosis patients.
The flouroquinolone (FQ) antibiotics have become increas-
ingly important in the treatment of tuberculosis (TB). The FQs
are already a critical component of second-line therapy against
multidrug-resistant (MDR) TB (3, 14, 31). They are also under
study for use in first-line treatment of TB due to their potency
and potential sterilizing activity (9, 24). Unfortunately, FQ
resistance is being observed with increasing frequency in My-
cobacterium tuberculosis isolates that are otherwise fully drug
susceptible (15) and in isolates that are already MDR (17, 28,
30). FQ resistance is also an important part of the case defi-
nition of extensively drug-resistant (XDR) TB (14–17, 25).
These emerging trends have placed a new urgency on the
development of rapid methods to detect FQ resistance.
In M. tuberculosis, FQ resistance appears to be principally
caused by single-nucleotide polymorphisms in the M. tubercu-
losis gyrA gene. Between 60 and 90% of FQ-resistant clinical
M. tuberculosis isolates have mutations in a short 21-bp “quin-
olone resistance-determining region” (QRDR) of gyrA, partic-
ularly in codons 90, 91, and 94. Mutations in the M. tuberculosis
gyrB gene are also associated with FQ resistance, but at a much
lower frequency and usually in association with gyrA mutations
(9, 12, 18, 21, 23, 27). While most M. tuberculosis strains with
gyrA QRDR mutations are FQ resistant, virtually all strains
that are wild type in this region are FQ susceptible. The ex-
ception to this rule is a known polymorphism at gyrA codon 95.
FQ-susceptible M. tuberculosis strains can have either a threo-
nine (T) or a serine (S) allele at this location (95S or 95T,
respectively) (14). Consequently, a molecular test that can
differentiate between the two wild-type QRDR sequences and
any other possible QRDR mutation is able to identify FQ
resistance with high sensitivity and specificity. In fact, the gyrA
QRDR has emerged as an important biomarker for rapid
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detection of FQ resistance in M. tuberculosis and is increasingly
being used as a target for rapid molecular drug susceptibility
tests (6, 13, 20, 21, 26, 29).
A number of molecular methods to detect gyrA QRDR mu-
tations have been described recently, including line probe as-
says, locked nucleic acid probes, multiplex PCR amplimer con-
formation analysis (MPAC), denaturing high-performance
liquid chromatography (HPLC) heteroduplex analysis, and di-
rect sequencing (6, 11, 13, 20, 21, 26, 29). However, most of
these methods are technically challenging and involve handling
of PCR amplicons in open tubes, which can lead to amplicon
cross-contamination and diminished assay specificity. The ex-
tensive washing steps and on-membrane hybridization re-
quired by some of the most commonly used techniques also
complicate assays and increase assay time (21). No rapid real-
time PCR-based method to detect FQ resistance has been yet
described. This is likely due to the technical challenge of iden-
tifying multiple different mutations in a simple real-time PCR
assay.
We have recently described a melting temperature (Tm)-
based method that uses asymmetrical PCR in conjunction with
sloppy molecular beacons (SMBs) to identify hundreds of dif-
ferent target sequences (4). Here, we investigate whether this
approach can be adapted to detect all of the gyrA QRDR
mutations associated with FQ-resistant M. tuberculosis in a
simple, rapid, and highly specific single-well assay. In addition,
we studied the capacity of this approach to detect mixtures of
wild-type and mutant DNA, since we had identified a subset of
clinical FQ-resistant TB cases that had heteroresistance in
their clinical cultures.
MATERIALS AND METHODS
Clinical DNA samples. DNA samples from FQ-resistant and FQ-susceptible
clinical M. tuberculosis isolates were collected from the National Masan Tuber-
culosis Hospital by the International Tuberculosis Research Center (ITRC),
Masan, South Korea; the Public Health Research Institute (PHRI), Newark, NJ;
and the WHO TDR Tuberculosis Specimen Bank (5). M. tuberculosis cultures
from drug-susceptible and FQ-resistant XDR patients were selected from pa-
tients enrolled in a natural history study in Korea. All samples underwent DNA
sequencing, and 30 samples representing a wide variety of QRDR mutations,
including some wild-type control samples, were selected for testing with the SMB
assay. Another set of 41 DNA samples originated from patients with culture-
positive tuberculosis from the New York/New Jersey area that had been tested
for QRDR mutations by mass spectrometry analysis. This set of DNA samples
was also chosen to represent a wide repertoire of the common QRDR mutations,
along with a sampling of isolates with wild-type QRDR sequences. Finally a set
of 21 DNA samples from MDR TB isolates (with no known XDR cases) from
Asia, Africa, and Latin America maintained by the United Nations Children’s
Fund/UNDP/World Bank/WHO Special Program for Research and Training in
Tropical Diseases were chosen to represent wild-type gyrA QRDR controls to
complete our study sample set (Table 1). We confirmed the sequence of the gyrA
QRDR in all 92 DNA samples by DNA sequencing. Out of the 21 samples from
the WHO TDR collection chosen to represent wild-type gyrA QRDR, two sam-
ples turned out to harbor mutant QRDR sequences, one having a D94A T allele
mutation and the other being a mixture of wild-type and D89N T allele se-
quences. Each DNA sample was quantified with Nanodrop microvolume spec-
trophotometer (Thermo Scientific), and 2 to 4 ng of the DNA sample was used
for PCR. All samples were independently coded and randomly redistributed to
blind the sample sequence and origin before assay testing.
DNA samples from nontuberculous mycobacteria (NTM) and Gram-positive
and Gram-negative bacteria. One hundred twenty-one clinical NTM DNA iso-
lates representing 26 species, including M. abcessus, M. aubagnense, M. avium, M.
avium subsp. paratuberculosis, M. bollettii, M. celatum, M. chelonae, M. flavescens,
M. fortuitum, M. gastri, M. genevense/M. simiae, M. gordonae, M. intermedium, M.
intracellulare, M. kansasii, M. malmoense, M. mucogenicum, M. peregrinum, M.
porcinum, M. scrofulaceum, M. senegalense, M. shimoidei, M. smegmatis, M.
simiae, M. szulgai, M. terrae, and M. xenopi, with several mixed samples containing
more than one NTM species, were obtained from ITRC. For evaluation of assay
specificity, a panel of 18 species of Gram-negative and Gram-positive bacteria
representing the most common bloodstream infection and nosocomial pathogens
was also selected: Acinetobacter baumanii, Bacillus cereus, Clostridium difficile,
Campylobacter jejuni, Escherichia coli, Haemophilus influenzae, Klebsiella pneu-
moniae, Listeria grayi, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylo-
coccus epidermidis, Staphylococcus hominis, Streptococcus agalactiae, Streptococ-
cus dysgalactiae, Streptococcus pyogenes, Streptococcus pneumoniae, Vibrio
cholerae, and Yersinia enterocolitica. DNA was either isolated from pure clinical
strains by boiling a loopful of culture in Instagene matrix (Bio-Rad), or pure
genomic DNA from ATCC strains was obtained from BEI Resources (Manassas,
VA). The DNA was quantified as described above and used to determine the
analytical specificity of the assay, using 5 to 10 ng of the DNA samples for PCR.
SMBs and primers. A 107-bp fragment (nucleotides 222 to 330, with number-
ing based on the gene start site) containing the gyrA QRDR was amplified with
the target primer gyrA-F (5-CCGGTCGGTTGCCGAGACC-3) and the anti-
sense primer gyrA-R (5-CCAGCGGGTAGCGCAGCGACCAG-3). These
primers were designed to be specific to the M. tuberculosis complex, verified by
an alignment of M. tuberculosis and all of the NTM gyrA sequences available in
the database (http://www.ncbi.nlm.nih.gov/GenBank/) (7). The two SMB se-
quences were QDR1 (5-6-carboxyfluorescein CCGTGCgcgcaccagggtgccctagatc
gacacgtcGCACGG-DABCYL-3) and QDR2 (5-cyanine 5-CCCGAGGgItgtcg
tagattgacacgtcgccgcgcggCCTCGGG-BHQ1-3), where the underlined uppercase
sequences represent the stem portion and the lowercase sequences represent the
probe portion of the SMBs, DABCYL represents 4-(4-dimethylamino)phenylazo-
benzoic acid, BHQ represents Black Hole quencher, and I represents deoxyinosine.
Both probes were targeted against the gyrA QRDR region. The SMBs were designed
by using the in silico DNA folding program from http://frontend.bioinfo.rpi.edu
/applications/mfold/cgi-bin/dna-form1.cgi, and the probe-target hybrid folding pro-
gram from http://dinamelt.bioinfo.rpi.edu/twostate.php was used to predict the pos-
sible probe-target hybrid structures and melting temperatures (Tms). The probes
were designed to generate a maximum Tm difference between wild-type and mutant
sequences, so as to enable their unambiguous identification. Primers were obtained
from Sigma Genosys, and the SMB probes were obtained from Biosearch, CA.
Artificial templates containing gyrA core region mutations. We designed ar-
tificial oligonucleotide templates for all of the documented QRDR mutations.
These were then used to test the efficacy of the probes to identify each mutation
and the two wild-type polymorphisms. Each oligonucleotide template included
the sequences of the gyrA QRDR and the binding sites of the assay’s primers.
Separate templates were made for each of the mutations G88C, G88A, D89N,
A90V, S91P, D94A, D94G, D94N, D94Y, and D94H on both 95S and 95T gyrA
allele wild-type sequence backgrounds [designated as gyrA(95S) and gyrA(95T),
respectively]. Approximately 105 molecules of each template were used in each
PCR assay containing the primers and the SMB probes.
Sloppy molecular beacon melt assay. A PCR-Tm analysis assay was carried out
on artificial templates and clinical sample DNA as follows. All studies of DNA
from clinical samples were performed and decoded by an experimenter who was
blinded to the nature and identity of the sample. PCR was performed with the
Roche Light Cycler 480 II real-time PCR system (Roche Molecular Systems,
Inc.), in 20-l reaction volumes containing 1 M target primer and 100 nM
antisense primer, 0.8 ng/l of each SMB probe, 4 mM MgCl2, 250 mM de-
oxynucleoside triphosphates (dNTPs), 1 PCR buffer, 5% glycerol, 0.06 U/l of
AmpliTaq gold Stoffel DNA polymerase (Applied Biosystems), and 2 to 5 ng of
sample DNA or an equivalent volume of water. PCR was carried out as follows:
activation of the enzyme for 2 min at 95°C, followed by 45 cycles of denaturation
at 95°C for 15 s, annealing at 65°C for 30 s, and extension at 72°C for 10 s.
Following PCR cycling, post-PCR-Tm analysis was performed by denaturation at
95°C for 5 min, followed by cooling down to 45°C and then gradual heating to
85°C with continuous monitoring of the fluorescence during the process at a rate
of 15 data acquisitions per °C. Tm calls were performed at the end of the reaction
by using the automated Tm calling software (Light Cycler 480 software), and the
resulting Tm values for each probe were determined. Double peaks were
automatically identified by the Tm calling software, indicating the presence of
mixed DNA.
DNA mixtures containing wild-type and mutant DNA. DNA mixtures contain-
ing wild-type and mutant DNA were prepared to evaluate the performance of
the assay to detect presence of heteroresistance. Various amounts of mutant
genomic DNA (obtained from the clinical isolates) were added to the wild-type
DNA to generate DNA mixtures containing 5, 10, 20, 30, and 40% mutant DNA
in a total amount of 1 ng (105 genome equivalents) of DNA. The most common
gyrA QRDR mutant DNA types, A90V, S91P, and D94G (11, 21), were individ-
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ually mixed with wild-type DNA [all having gyrA(95T) alleles], and SMB Tm shift
assays were performed to determine the limit of the assay to identify the mutant
sequence in the presence of a large wild-type DNA background.
RESULTS
SMB design. We have previously shown that SMBs can be
used to identify NTM species (10) or to distinguish among a
wide variety of pathogenic Gram-positive and Gram-negative
bacteria (4). SMBs differ from conventional molecular beacons
in having unusually long probe sequences, which enable them
to query long stretches of DNA and to increase their mismatch
tolerance (4). To identify FQ resistance mutations, we de-
signed two SMBs, QDR1 and QDR2, with 30-bp probe se-
quences and 6- to 7-bp stem sequences (Fig. 1). The probes
were designed to generate stable stem-loop structures while
avoiding the formation of secondary structures in the loop
TABLE 1. Two Tm codes for the clinical isolate DNA and their concordance with DNA sequence analysis
Sample
no.
Tm value (°C) by: QRDR type bya: Sample
no.
Tm value (°C) by: QRDR type bya:
QDR1-FAM QDR2-Cy5 Tm prediction Sequencing data QDR1-FAM QDR2-Cy5 Tm prediction Sequencing data
1 64.6 63.2 WT T WT T
2 64.6 63.2 WT T WT T 51 61.6 57.3 G88A T G88A T
3 64.6 63.3 WT T WT T 52 65.5 65.4 A90V S A90V S
4 64.5 63.1 WT T WT T 53 65.7 65.4 A90V S A90V S
5 64.6 63.2 WT T WT T 54 68.3 66.9 A90V T A90V T
6 64.5 63.5 WT T WT T 55 68.3 66.9 A90V T A90V T
7 64.5 63.3 WT T WT T 56 68.3 66.9 A90V T A90V T
8 64.6 63.3 WT T WT T 57 68.3 67.3 A90V T A90V T
9 64.5 63.1 WT T WT T 58 68.3 66.7 A90V T A90V T
10 64.9 63.8 WT T WT T 59 68.2 66.6 A90V T A90V T
60 68.3 66.7 A90V T A90V T
11 64.5 63.2 WT T WT T
12 64.5 63.2 WT T WT T 61 68.2 66.7 A90V T A90V T
13 64.6 63.4 WT T WT T 62 68.5 66.8 A90V T A90V T
14 64.5 63.1 WT T WT T 63 68.3 66.7 A90V T A90V T
15 64.4 63.2 WT T WT T 64 68.3 66.7 A90V T A90V T
16 64.4 63.2 WT T WT T 65 58.8 58.6 S91P T S91P T
17 64.6 63.3 WT T WT T 66 58.6 58.3 S91P T S91P T
18 64.5 63.2 WT T WT T 67 58.6 58.2 S91P T S91P T
19 64.6 63.3 WT T WT T 68 58.6 58.3 S91P T S91P T
20 64.5 63.3 WT T WT T 69 58.5 58.3 S91P T S91P T
70 66.2 59.1 D94G S D94G S
21 64.4 63.0 WT T WT T
22 64.4 63.8 WT T WT T 71 68.3 60.6 D94G T D94G T
23 64.6 63.2 WT T WT T 72 68.4 60.5 D94G T D94G T
24 64.4 63.2 WT T WT T 73 68.4 60.5 D94G T D94G T
25 64.3 63.0 WT T WT T 74 68.3 60.5 D94G T D94G T
26 64.3 63.1 WT T WT T 75 68.3 60.5 D94G T D94G T
27 64.4 63.1 WT T WT T 76 68.5 60.7 D94G T D94G T
28 64.3 63.0 WT T WT T 77 68.2 60.3 D94G T D94G T
29 64.3 62.9 WT T WT T 78 68.3 60.4 D94G T D94G T
30 64.4 63.2 WT T WT T 79 68.2 60.3 D94G T D94G T
80 62.9 57.4 D94H/N/Y T D94N T
31 64.3 63.1 WT T WT T
32 64.3 63.0 WT T WT T 81 64.2 58.6 G88C T or D94A T D94A T
33 64.3 63.1 WT T WT T 82 60.0 54.5 G88C S or D94H/ D94H S
34 64.4 63.2 WT T WT T N/Y S
35 64.3 63.0 WT T WT T 83 71.7 64.0 New mutant/double A90V T D94G T
36 64.6 63.2 WT T WT T mutant
37 64.3 62.9 WT T WT T 84 69.8 63.3 New mutant/double A90V T D94G T
38 64.4 62.9 WT T WT T mutant
39 64.4 62.9 WT T WT T 85 63.6 57.7–63.5 WT T  G88C or WT T  D94A T
40 64.3 62.8 WT T WT T D94A T
86 63.7–68.0 62.5–67.3 WT T  A90V T WT T  A90V T
41 64.2 62.9 WT T WT T 87 59.1–64.6 58.6–63.3 WT T  S91P T WT T  A90V 
42 64.3 62.8 WT T WT T S91P T
43 64.3 62.9 WT T WT T 88 64.2–68.5 63.12–66.9 WT T  A90V T WT T  A90V T
44 64.3 62.8 WT T WT T 89 58.5–64.5 62.9 Mixed DNA WT T  D89N T
45 64.3 62.8 WT T WT T 90 65.4–69.9 59.8 Mixed DNA D94G T  D94A T
46 64.3 62.9 WT T WT T 91 64.2 57.6–63.3 WT T  D94H/N/ WT T  D94N T
47 61.3 61.3 WT S WT S Y T
48 61.4 61.3 WT S WT S 92 63.0 57.5–63.3 WT T  D94H/N/ WT T  D94N T
49 61.6 61.5 WT S WT S Y T
50 61.3 61.5 WT S WT S
a WT, wild type; T, 95T allele (threonine); S, 95S allele (serine).
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region (Fig. 1A). The QDR1 probe spanned gyrA codons 89 to
98, while the QDR2 probe spanned gyrA codons 86 to 95 (Fig.
1B). We deliberately introduced mutations into the SMB
probe sequences to disrupt secondary structures and palin-
dromes and to generate a stable stem-loop structure that op-
timized probe-target hybridization kinetics. This is in contrast
to conventional molecular beacons, which are designed to be
fully complementary to their target sequences. In selecting
probe sequence mutations, we attempted to incorporate com-
monly occurring FQ resistance-associated gyrA QRDR muta-
tions if possible. However, unrelated mutations were also in-
troduced into the probes if naturally occurring mutations did
not result in good probe structures. The QDR1 probe con-
tained the A90V and D94G FQ resistance-associated muta-
tions. It also contained an unrelated mutation in codon 93. The
QDR2 probe contained the same A90V FQ resistance-associ-
ated mutation. It also contained two unrelated mutations in
codons 87 and 91 (Fig. 1A and B). As a result, the similarity of
probe QRD1 to both A90V and D94G mutations and that of
QDR2 to the D94G mutation was higher than their relatedness
to the wild-type QRDR sequence. Likewise, the similarity of
the SMBs to the S91P mutant and less common FQ-resistant
mutants was lower than their similarity to FQ-susceptible wild-
type M. tuberculosis. Therefore, each SMB had a gradient of
probe-target relatedness, with common mutants being recog-
nized more effectively than the wild type and the wild type
more effectively than less common mutations. This approach
increased the range of Tms produced by the assay, thereby
increasing assay precision (Table 1). It also aided in the iden-
tification of mutant DNA in wild-type DNA mixtures (Fig. 2).
Melting temperature profiles. We tested the ability of the
two SMBs to identify QRDR mutations in both the gyrA(95S)
and gyrA(95T) allele backgrounds. Artificial QRDR targets
were constructed containing all known wild-type and QRDR
mutant sequences and tested in the two-SMB assay. Table 2
shows the average Tm values obtained from 10 individual as-
says for each artificial template. We found that the assay pro-
duced distinct and reproducible Tm values that distinguished
the two wild-type polymorphisms from all of the QRDR mu-
tations, regardless of the gyrA(95T or 95S) allele background.
Notably, the difference between the Tm values (dTm) of the
wild-type target and each mutant target was at least 3.6°C for
at least one of the two SMBs, indicating that differentiation
between wild-type and mutant sequences was likely to be ro-
bust (Table 2). We had previously shown that SMB-generated
Tms can be used in combination to derive an allele-specific
code that identifies bacterial species (4). In this study, we
tested whether the two SMBs used in the assay could generate
dual Tm codes that specifically identified each mutation. The
results show that the two QRDR-specific SMBs generated Tm
codes that distinguished between the two wild-type polymor-
phisms and the most highly prevalent QRDR A90V, S91P,
and D94G mutants (11, 21) [for both gyrA(95S) and
gyrA(95T) alleles], as well as the G88A [gyrA(95T)] and
D89N [gyrA(95S)] mutants. The Tm codes generated in the
assay divided the other mutants into four groups containing
(i) the G88A [gyrA(95S)] and D89N [gyrA(95T)] mutants,
(ii) G88C [gyrA(95S)] and D94H/N/Y [gyrA(95S)] mutants,
(iii) G88C [gyrA(95T)] and D94A [gyrA(95T) mutants, and
(iv) the D94H/N/Y [gyrA(95T)] mutant. In clustering the
mutant and wild-type sequences based on their individual
Tm codes, we considered Tm codes to be identical, unless at
least one of the Tm values between the Tm codes differed by
2°C and above to compensate for experimental variability.
Importantly, all mutations were clearly differentiated from
wild-type sequences (Table 2).
Clinical FQ-resistant M. tuberculosis DNA with either the
gyrA(95S) or the gyrA(95T) allele harboring all of the known
QRDR mutations, except G88C, D89N, and D94Y, were avail-
able in our study sample set. We tested the assay with each of
these 11 QRDR mutant DNA samples, and the resulting dual
Tm codes paralleled the results with the oligonucleotide tem-
plates, except each Tm was 1.5 to 2°C lower on average (see
Table S1 in the supplemental material). This difference in Tm
values is consistent with our previous experience in moving
from oligonucleotides to genomic DNA samples (10) and does
not affect assay performance, since the change is maintained
across both mutant and wild-type DNAs.
Analytical specificity of the assay for M. tuberculosis. The
analytical specificity of the assay was tested against a panel of
139 DNA samples representing 26 different NTM species and
18 Gram-negative and Gram-positive pathogenic bacteria. No
signals were obtained with any of bacteria, except for 9/22 M.
abcessus samples (data not shown). However, the positive M.
abcessus samples caused only one of the two SMBs in the assay
(QDR2) to generate a Tm of 55 to 56°C. This resulted in a Tm
code that was unique to M. abcessus and that could not be
confused with either wild-type or mutant M. tuberculosis.
Detection of DNA mixtures. We have observed that a num-
ber of samples from patients with XDR TB contain mixtures
FIG. 1. Assay probes and target. (A) SMB probe structures. The
structures for SMB QDR1 and QDR2 are shown. Mutations in the
loop region are indicated in uppercase, and those corresponding to
known QRDR mutations are shown in green. Uppercase letters in
black show the probe stems. (B) Probe target alignments. Among the
three sequences shown, “gyrA” indicates the gyrA QRDR, “QDR1”
indicates the reverse complement of the QDR1 SMB probe sequence,
and “QDR2” indicates the reverse complement of the QDR2 SMB
probe sequence. The gyrA codons associated with FQ resistance mu-
tations are marked in red and blue, and their codon numbers are
indicated. The mutations introduced into the two SMB sequences are
identified by uppercase letters. S denotes either cytosine or guanine,
and I denotes deoxyinosine.
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of wild type (FQ-susceptible) and QRDR mutant (FQ-re-
sistant) M. tuberculosis. Mutant detection is challenging in
real-time PCR tests in a background of large amounts of
wild-type DNA (2). However, we postulated that our probe
design criteria, which resulted in large dTms between wild-
type and mutant targets, would enable us to detect mutant
targets even when they were present as a minor proportion.
To test this, we mixed M. tuberculosis genomic DNA from
strains that had a wild-type QRDR with strains that had a
mutant QRDR to create artificial mixtures with various pro-
portions of mutant target. Three different common QRDR
mutants (S91P, A90V, and D94G) were tested in this man-
ner with the SMB assay. Mixtures of wild-type and mutant
DNA were detected as double Tm peaks from the QDR1
SMB, the QDR2 SMB, or both (Fig. 2). We observed that
mutant detection was somewhat dependent on the actual
mutation that was present in the mixture. Thus, the assay
could detect 5% D94G DNA mixed with 95% wild-type
FIG. 2. Tm profiles of DNA mixtures. The Tm curve for the indicated SMB is shown in an assay containing various mixtures of wild-type and
mutant clinical M. tuberculosis DNA. (A) SMB QDR1 tested with wild-type plus D94G mutant DNA. Panel 1, individual wild-type and mutant
DNA samples; panel 2, 5% mutant and 95% wild-type DNA; panel 3, 10% mutant and 90% wild-type DNA; panel 4, 20% mutant and 80%
wild-type DNA; panel 5, 30% mutant and 70% wild-type DNA. (B) SMB QDR1 tested with wild-type plus S91P mutant DNA; (C) SMB QDR2
tested with wild-type plus S91P mutant DNA; (D) SMB QDR1 tested with wild-type plus A90V mutant DNA; (E) SMB QDR2 tested with
wild-type plus A90V mutant DNA. In panels B to E, panel 1 contains individual wild-type and mutant DNA samples, panel 2 contains 10% mutant
and 90% wild-type DNA, panel 3 contains 20% mutant and 80% wild-type DNA, and panel 4 contains 30% mutant and 70% wild-type DNA. All
of the wild-type and mutant DNA had the gyrA(95T) allele.
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DNA (Fig. 2A), but required at least 10% S91P and 10%
A90V mutant DNA in the mixture for efficient detection
(Fig. 2B to E). The QDR1 SMB was better able to detect
mixtures than the QDR2 SMB. This is likely due to the
larger dTm between wild-type and mutant DNA observed
with QDR1 for these three mutations (Fig. 2 and Table 2).
We tested a series of mixtures in a blinded manner to further
validate the assay for heteroresistance detection. Mutant and
wild-type DNA was mixed in various proportions, and then
each sample was split into eight different aliquots. All aliquots
were then tested with the assay after blinding. We found that
samples containing at least 10% D94G or S91P mutants could
be detected in 100% of test replicates. Samples containing at
least 20% A90V mutants could be detected in 100% of the test
replicates, although samples containing 10% A90V could be
detected in only 50% of the test replicates. Thus, our assay
showed good consistency in the ability to detect mutant and
wild-type DNA mixtures.
Assay performance on blinded clinical DNA samples. We
next tested the performance of the assay on 92 clinical M.
tuberculosis isolates, including genomic DNA isolated from
FQ-sensitive and FQ-resistant clinical cultures. Each DNA
sample was coded, and the SMB assay was performed blindly.
The assay showed 100% concordance with sequencing results
for wild-type, mutant, double mutant, and mutant–wild-type
mixed-DNA samples (Table 1). Each type of individual
QRDR mutation and the two wild-type polymorphisms
showed distinct peak profiles (Fig. 3). Thus, each mutation
could be identified by the distinct dual Tm codes that it




Tm (°C) dTm (°C)c Tm (°C) dTm (°C)c
WT T 66.2 65.4
G88A T 61.7 4.4 58.1 7.4
G88C T 66.0 0.2 60.5 5.0
D89N T 60.3 5.9 58.3 7.2
A90V T 69.8 3.6 68.0 2.6
S91P T 61.3 4.9 62.6 2.8
D94A T 66.1 0.1 60.3 5.1
D94G T 70.3 4.2 63.5 1.9
D94H T 65.0 1.2 58.8 6.6
D94N T 64.9 1.3 58.8 6.6
D94Y T 64.8 1.4 58.2 7.3
WT S 63.8 64.6
G88A S 59.0 4.8 57.4 7.3
G88C S 63.5 0.3 57.4 7.2
D89N S 57.2 6.6 58.4 6.2
A90V S 67.5 3.8 67.8 3.2
S91P S 58.9 4.9 59.3 5.3
D94A S 63.9 0.1 59.3 5.4
D94G S 68.3 4.6 62.0 2.7
D94H S 62.5 1.3 56.7 8.0
D94N S 62.5 1.3 56.6 8.0
D94Y S 62.4 1.4 56.6 8.0
a Results represent the average of 10 separate reactions. Tm values did not
differ by more than 0.5 to 0.8°C.
b WT, wild type; T, 95T allele (threonine); S, 95S allele (serine).
c dTm  WT Tm  mutant Tm. Negative dTm values imply a higher Tm for the
probe with the mutant sequence than that for the wild-type sequence.
FIG. 3. Dual Tm profiles of wild-type and QRDR mutant DNA. The Tm profiles of SMB QDR1 and QDR2 are shown in the presence of
wild-type clinical M. tuberculosis DNA and various clinical QRDR mutants. The dual Tm peaks (°C) of each profile are listed in parentheses.
(A) Wild-type gyrA(95T) (64.6 and 63.2); (B) wild-type gyrA(95S) (61.5 and 61.4); (C) G88A gyrA(95T) mutant (60.8 and 57.3); (D) A90V gyrA(95T)
mutant (68.3 and 65.4); (E) A90V gyrA(95S) mutant (65.5 and 65.4); (F) S91P gyrA(95T) mutant (58.8 and 58.6); (G) D94A gyrA(95T) mutant (64.2
and 58.6); (H) D94G gyrA(95T) mutant (68.3 and 60.6); and (I) D94N gyrA(95T) mutant (62.9 and 57.4).
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generated in the assay (Fig. 4A). The Tm values were highly
reproducible. Each SMB generated Tm values that differed
by less than 1°C in the presence of different samples with
identical QRDR sequences (Fig. 4A). Forty-two out of 46
wild-type QRDR strains had the gyrA(95T) allele, while the
other four strains had the gyrA(95S) allele. Among the
QRDR mutants, the A90V mutation predominated (13 mu-
tants), followed by D94G (10 mutants) and S91P (5 mu-
tants), consistent with previous studies (11, 21). Only one
G88A, D94N, D94A, and D94H mutation each was detected
in our study set, and two strains had both A90V and D94G
mutations in the QRDR. As with the wild-type strains, the
gyrA(95T) allele predominated in the QRDR mutants (Ta-
ble 1).
Nearly 9% (8/92) of the clinical DNA included in our study
showed the presence of heteroresistance, with seven samples
containing both wild-type and QRDR mutant sequences and
one containing a mixture of D94A and D94G mutants, which
was confirmed by DNA sequencing. Our assay identified all of
the mixed samples as mixtures by detecting distinct double
peaks in either one or both of the SMBs. Deconvolution of the
Tm peaks to generate multiple Tm codes allowed us to correctly
identify a mixture of mutant and wild-type sequence in five of
the eight DNA mixtures (Table 1 and Fig. 4B). One sample
was found to contain a mixture of A90V, S91P, and wild-type
gyrA(95T) allele DNA on sequencing, but an analysis of the
dual Tm codes only revealed a mixture of A90V and wild-type
sequences. Two other samples could be identified only as
mixed DNA as the double Tm peaks could not be deconvoluted
into meaningful Tm codes. DNA sequencing showed the pres-
ence of wild-type and D89N gyrA(95T) alleles in one sample
and a mixture of D94G and D94A gyrA(95T) allele mutants in
the other.
An additional two samples contained two QRDR mutations
on the same DNA sequence (samples 83 and 84 in Table 1).
Assays performed on these samples resulted in unique single
Tm peaks for each SMB, and their Tm codes did not match any
known Tm code for the wild-type alleles or the individual
QRDR mutations (Fig. 4A, samples 83 and 84). DNA sequenc-
ing revealed that these two samples contained A90V and
D94G gyrA(95T) allele mutations (Table 1). These two cases
demonstrate that combinations of mutations may produce new
Tm codes that are specific for that combination and different
from the wild type or the single QRDR mutants.
DISCUSSION
We have successfully designed SMBs that identify specific
gyrA QRDR mutations and mutant–wild-type mixtures. The
dual Tm codes generated in the assay easily differentiated be-
tween wild-type DNA derived from FQ-susceptible M. tuber-
culosis and mutant DNA derived from FQ-resistant M. tuber-
culosis. The codes also enabled us to identify each mutation in
the QRDR and to identify mixed samples containing 5 to 20%
mutant DNA. The assay was rapid and robust, and unlike
techniques which involve open DNA hybridization, the assay
was technically quite simple. The SMB approach allowed the
query of the entire gyrA QRDR region with only two probes in
an enclosed system. This approach is technically much simpler
and robust than existing assays, which use as many as nine
probes to identify the gyrA QRDR mutations (21). There was
a 100% concordance between our assay results and DNA se-
quencing.
Our assay was also highly specific for M. tuberculosis. To the
best of our knowledge, this is the first study of a QRDR assay
which has looked at assay specificity. The M. tuberculosis gyrA
QRDR is quite similar to other organisms, and the mutations
encountered in FQ-resistant M. tuberculosis clinical isolates
have been found in similar regions of the gyrA gene from other
FQ-resistant bacteria (27). Assays with more limited specificity
might falsely identify NTM or other bacteria as FQ-resistant
M. tuberculosis. Although this problem could be partially ad-
dressed by including an M. tuberculosis-specific probe in each
assay, samples containing mixtures of NTM and M. tuberculosis
might still be falsely identified as FQ-resistant TB. This is
especially important in settings where NTM infections are
FIG. 4. Dual Tm codes of the clinical M. tuberculosis DNA tested in
this study. The Tm values of each SMB are shown for 92 clinical M.
tuberculosis isolates ordered by mutation and gyrA(95S or 95T) allele.
Each QRDR sequence type is seen to generate distinct dual Tm pro-
files. (A) Tm codes of homogeneous DNA samples. Samples 1 to 46,
wild-type gyrA(95T); samples 47 to 50, wild-type gyrA(95S); samples 51
and 52, A90V gyrA(95S) mutant; samples 53 to 63, A90V gyrA(95T)
mutant; samples 64 to 68, S91P gyrA(95T) mutant; samples 69 to 77,
D94G gyrA(95T) mutant; sample 78, G88A gyrA(95T) mutant; sample
79, D94N gyrA(95T) mutant; sample 80, D94A gyrA(95T) mutant;
sample 81, D94G gyrA(95S) mutant; sample 82, D94H gyrA(95S) mu-
tant; and samples 83 and 84, A90V D94G gyrA(95T) double mutant.
(B) Tm codes of the mixed clinical samples. Either one or both probes
can be seen to have generated double peaks with distinct Tm values.
Sample 1, wild type and D94A mutant; samples 2 and 4, wild type and
A90V mutant; sample 3, wild type and A90V and S91P mutants;
sample 5, wild type and D89N mutant; sample 6, D94A and D94G
mutants; samples 7 and 8, wild type and D94N mutant. All of the
samples contained the gyrA(95T) allele.
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highly prevalent. We tested our assay against an extensive
panel of NTM and other pathogenic bacteria: only M. ab-
cessus resulted in any Tm signal, and this was only with one
of the two probes (QDR2). However this Tm was different
from any Tm we have observed in any M. tuberculosis QRDR
mutant. Also, none of the M. abcessus strains generated a
Tm value in QDR1. Thus, it is highly unlikely that our assay
would mistakenly identify an M. abcessus sample as FQ-
resistant M. tuberculosis, even when M. tuberculosis was
mixed into the sample.
FQ heteroresistance appears to be a relatively common oc-
currence (1, 9, 11, 21, 22), with some studies reporting that as
many as 22 to 31% of patients with FQ-resistant TB were
infected with both wild-type and QRDR mutant M. tuberculo-
sis strains (9, 21). We tested our assay’s ability to detect the
presence of mutant DNA mixed into a large wild-type DNA
background and found that the assay detected as little as 5% of
the mutant sequence present in a DNA sample. Mutations
were consistently detected at 10 to 20% concentrations.
These results suggest that the assay will be useful for de-
tecting early development of FQ-resistant TB. Almost 9% of
our test panel came from patients who were found to have
heteroresistance, and the assay detected the mixed infection
in every case.
Our assay has the potential to complement and extend the
utility of other real-time PCR tests such as the Xpert MTB/
RIF assay, recently released commercially. The Xpert assay
rapidly detects the presence of M. tuberculosis with sensitiv-
ity close to that of culture and identifies the presence of
rifampin resistance (19). Patients identified as rifampin re-
sistant by the Xpert assay are at increased risk for XDR TB.
Our assay could be used to screen for FQ resistance in these
rifampin-resistant patients, thereby identifying the subset of
patients most likely to have XDR. Our assay will have much
broader utility if FQs become recommended as part of pri-
mary TB therapy. Recent reports suggest that FQ exposure
for more than 10 days that predated 60 days before the
diagnosis of active tuberculosis was associated with as high
as a 20.8% risk of resistance (8). This suggests that FQ-
resistant TB will become more common if FQs continue to
be used to treat respiratory infections. First-line therapy
with an FQ-containing regime could have disastrous conse-
quences in patients with unrecognized primary FQ resis-
tance. We suggest that the incidence of primary FQ resis-
tance is already sufficiently high to justify prescreening all
new TB patients with a rapid FQ resistance assay before
they are treated with an FQ-containing regime. In summary,
we have developed a rapid, simple, and robust method to
detect M. tuberculosis gyrA QRDR mutations associated
with FQ resistance. This assay will be a useful tool for rapid
molecular drug susceptibility testing of FQ resistance and
for detecting the early emergence of FQ heteroresistance in
TB patients.
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